Cargando…
Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
Liraglutide is a glucagon-like peptide-1 receptor agonist used as a treatment for type 2 diabetes mellitus, which has been expanded for use at a higher dose in weight control. Therefore, it is necessary to consider adverse reactions of the drug at high doses as well as at lower doses after the indic...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for the Study of Obesity
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017323/ https://www.ncbi.nlm.nih.gov/pubmed/33071241 http://dx.doi.org/10.7570/jomes20059 |
_version_ | 1783674041801900032 |
---|---|
author | Seo, Young-Gyun |
author_facet | Seo, Young-Gyun |
author_sort | Seo, Young-Gyun |
collection | PubMed |
description | Liraglutide is a glucagon-like peptide-1 receptor agonist used as a treatment for type 2 diabetes mellitus, which has been expanded for use at a higher dose in weight control. Therefore, it is necessary to consider adverse reactions of the drug at high doses as well as at lower doses after the indication has been expanded. Body mass index criteria for patients prescribed the drug in the real world tend to be applied less rigorously, which may increase the number of adverse reactions due to over-prescription. Liraglutide treatment was found effective and safe in some studies, while others have warned about its risks. Therefore, this review summarizes the current data available on side effects associated with liraglutide. |
format | Online Article Text |
id | pubmed-8017323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Korean Society for the Study of Obesity |
record_format | MEDLINE/PubMed |
spelling | pubmed-80173232021-04-02 Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes Seo, Young-Gyun J Obes Metab Syndr Review Liraglutide is a glucagon-like peptide-1 receptor agonist used as a treatment for type 2 diabetes mellitus, which has been expanded for use at a higher dose in weight control. Therefore, it is necessary to consider adverse reactions of the drug at high doses as well as at lower doses after the indication has been expanded. Body mass index criteria for patients prescribed the drug in the real world tend to be applied less rigorously, which may increase the number of adverse reactions due to over-prescription. Liraglutide treatment was found effective and safe in some studies, while others have warned about its risks. Therefore, this review summarizes the current data available on side effects associated with liraglutide. Korean Society for the Study of Obesity 2021-03-30 2020-10-19 /pmc/articles/PMC8017323/ /pubmed/33071241 http://dx.doi.org/10.7570/jomes20059 Text en Copyright © 2021 Korean Society for the Study of Obesity This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Seo, Young-Gyun Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes |
title | Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes |
title_full | Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes |
title_fullStr | Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes |
title_full_unstemmed | Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes |
title_short | Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes |
title_sort | side effects associated with liraglutide treatment for obesity as well as diabetes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017323/ https://www.ncbi.nlm.nih.gov/pubmed/33071241 http://dx.doi.org/10.7570/jomes20059 |
work_keys_str_mv | AT seoyounggyun sideeffectsassociatedwithliraglutidetreatmentforobesityaswellasdiabetes |